Balance Sheet Accounts and Supplemental Disclosures (Tables)

6 Months Ended

Jun. 30, 2026

Balance Sheet Accounts and Supplemental Disclosures [Abstract]

Schedule Of Property and Equipment

Property and equipment, net consist of the following:


(in thousands)		June 30, 2026				December 31, 2025
Laboratory equipment		$	6,765			$	6,723
Office furniture and equipment			1,583				1,583
Leasehold improvements(1)			—				203
Property and equipment, gross			8,348				8,509
Less: accumulated depreciation and amortization			(7,277	)			(7,139	)
Total property and equipment, net		$	1,071			$	1,370

(1)

All leasehold improvements remained with AnaptysBio as part of the Spin-Off.

Schedule Of Accrued Expenses

Accrued expenses consist of the following:


(in thousands)		June 30, 2026				December 31, 2025
Accrued compensation and related expenses		$	1,969			$	10,636
Accrued professional fees and other expenses			1,067				3,156
Accrued research, development and manufacturing expenses			4,422				12,040
Total accrued expenses		$	7,458			$	25,832

Schedule Of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(in thousands)		June 30, 2026				December 31, 2025
Receivable from AnaptysBio		$	4,226			$	—
Prepaid clinical development			2,470				2,851
Receivable from option exercises			848				29
Other current assets			2,183				1,882
Total prepaid expenses and other current assets		$	9,727			$	4,762